查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1288788

全球流感疫苗市场研究报告 - 行业分析、规模、份额、增长、趋势和2023至2030年预测

Global Influenza Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 289 Pages | 商品交期: 最快1-2个工作天内

价格

据推测，到2030年，全球对流感疫苗的需求将从2022年的10.5BN美元达到近26.751BN美元的市场规模，在2023-2030年的研究期间，复合年增长率为10.95%。

流感疫苗，或称流感疫苗，是一种可以预防流感的疫苗，是一种由流感病毒引起的高度传染性的呼吸道疾病。疫苗的作用是促使身体的免疫系统释放能够识别和抵御流感病毒的抗体。流感疫苗通常每年接种一次，通常在秋季或冬季，在流感季节开始之前。通常建议6个月以上的人接种疫苗，特别是患流感严重并发症风险较高的人，如老年人、有基础病的人和孕妇。

市场动态：

流感的高发率是流感疫苗市场的主要驱动力之一。流感是一种高度传染性的呼吸道疾病，可导致严重的并发症，特别是在高危人群（老年人和有潜在疾病的人）中。世界各国政府已经发起倡议，扩大疫苗接种率，减少流感对医疗系统的负担。这些倡议提高了人们对流感疫苗益处的认识，并增加了对疫苗的需求。疫苗技术的进步使流感疫苗的生产和分发变得更加容易。较新的疫苗技术，如重组DNA和细胞疫苗，与传统的蛋基疫苗相比，具有一些优势，如生产时间更快，疗效更好。发达国家和发展中国家不断增加的医疗开支正在推动流感疫苗市场的增长。政府和私营医疗机构正在投资于预防措施，如接种疫苗，以减少医疗系统的整体负担。老年人口的增长是流感疫苗市场的一个主要驱动力，因为老年人患流感的严重并发症的风险更高。

该研究报告包括波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清楚地了解行业结构，并在全球范围内评估竞争吸引力。此外，这些工具还对全球流感疫苗市场的每个细分市场进行了全面评估。流感疫苗行业的增长和趋势为这项研究提供了一个整体的方法。

区域分析：

这一部分涵盖了区域前景，强调了北美、欧洲、亚太、拉美、中东和非洲的流感疫苗市场的当前和未来需求。此外，该报告重点关注所有突出地区的个别应用部门的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况和对全球竞争格局的深入看法。流感疫苗市场的主要参与者包括GSK plc, AstraZeneca, SINOVAC, Pfizer Inc, Vaxess Technologies Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES。这一部分包括对竞争格局的整体看法，其中包括各种战略发展，如主要的合并和收购、未来的能力、伙伴关系、财务概况、合作、新产品的开发、新产品的推出以及其他发展。

目录

第1章：前言

  • 报告描述
    • 目的
    • 目标受众
    • 独特的销售主张（USP）和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法

第二章：执行摘要

  • 市场的亮点
  • 全球市场简介

第三章：流感疫苗 - 行业分析

  • 简介 - 市场动态
  • 市场驱动力
  • 市场限制因素
  • 机会
  • 行业趋势
  • 波特的五力分析
  • 市场吸引力分析
    • 市场吸引力分析（按疫苗类型
    • 市场吸引力分析（按适应症分类
    • 按年龄组分類的市场吸引力分析
    • 按给药途径分類的市场吸引力分析
    • 按销售渠道分類的市场吸引力分析
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原材料分析
    • 原材料清单
    • 原材料制造商名单
    • 关键原材料的价格趋势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 营销渠道的发展趋势

第五章：Covid-19疫情的影响分析

第六章：全球流感疫苗市场分析：按疫苗类型分类

  • 按疫苗类型概述
  • 历史和预测数据
  • 按疫苗类型分析
  • 灭活疫苗
  • 减毒活疫苗

第7章 ：全球流感疫苗市场分析：按适应症分类

  • 适应症概述
  • 历史和预测数据
  • 按适应症分析
  • 四价
  • 三价

第八章：全球流感疫苗市场分析：按年龄组分类

  • 按年龄组概述
  • 历史和预测数据
  • 按年龄组分析
  • 儿科
  • 成人

第九章：全球流感疫苗市场分析：按给药途径分类

  • 按给药途径的概述
  • 历史和预测数据
  • 按给药途径的分析
  • 注射剂
  • 鼻腔喷雾剂

第十章：全球流感疫苗市场分析：按分销渠道分类

  • 分销渠道概述
  • 历史和预测数据
  • 按分销渠道的分析
  • 医院和药店
  • 政府和机构供应
  • 其他渠道

第11章 ：全球流感疫苗市场分析：按地理区域划分

  • 顶级公司份额分析
  • 简介
  • 北美地区销售分析
    • 概述，历史和预测的销售分析
    • 北美地区分部销售分析
    • 北美洲国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概况、历史和预测的销售分析
    • 欧洲分部销售分析
    • 欧洲国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概况、历史和预测的销售分析
    • 亚太地区分部销售分析
    • 亚太地区国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 亚太其他地区销售分析
  • 拉美地区销售分析
    • 概况、历史和预测的销售分析
    • 拉美地区分部销售分析
    • 拉美地区国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概况、历史和预测销售分析
    • 中东和非洲地区分部销售分析
    • 中东和非洲国家销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 其他中东和非洲国家销售分析

第十二章 ：流感疫苗公司的竞争格局

  • 流感疫苗市场竞争
  • 伙伴关系/合作/协议
  • 合并和收购
  • 新产品发布
  • 其他方面的发展

第十三章 ：公司简介

  • 公司份额分析
  • 市场集中度
  • GSK plc
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • AstraZeneca
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • SINOVAC
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • Pfizer Inc
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • Vaxess Technologies Inc
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • CSL Limited
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • EMERGENT
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • Merck & Co. Inc.
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • Viatris Inc.
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • OSIVAX
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展
  • EMERGEX VACCINES
    • 公司概览
    • 公司收入
    • 产品
    • 近期发展情况

注意 - 在公司简介中，财务细节和最近的发展情况要视情况而定，如果是私营公司，可能不包括在内。

Product Code: VMR112110532

The global demand for Influenza Vaccine Market is presumed to reach the market size of nearly USD 26.751 BN by 2030 from USD 10.5 BN in 2022 with a CAGR of 10.95% under the study period 2023-2030.

Influenza vaccine, or flu shot, is a vaccine that protects against influenza, a highly contagious respiratory illness caused by influenza viruses. The vaccine works by prompting the body's immune system to release antibodies that can recognize and fight off the influenza virus. The influenza vaccine is typically given once a year, usually in the fall or winter, before the flu season begins. The vaccine is usually recommended for everyone over the age of six months, particularly individuals at higher risk of developing severe complications from influenza, such as the elderly, individuals with underlying medical conditions, and pregnant women.

Market Dynamics:

The high prevalence of influenza is one of the primary drivers of the influenza vaccine market. Influenza is a highly contagious respiratory illness that can lead to severe complications, particularly in high-risk populations (elderly and individuals with underlying medical conditions). Governments around the world have launched initiatives to scale up vaccination rates and reduce the burden of influenza on healthcare systems. These initiatives have led to increased awareness about the benefits of the influenza vaccine and increased demand for the vaccine. Advances in vaccine technology have made it easier to produce and distribute the influenza vaccine. Newer vaccine technologies, such as recombinant DNA and cell-based vaccines, offer several advantages over traditional egg-based vaccines, such as faster production times and improved efficacy. Increasing healthcare spending in developed and developing countries is driving the growth of the influenza vaccine market. Governments and private healthcare providers are investing in preventative measures such as vaccination to reduce the overall burden on healthcare systems. The growing elderly population is a key driver of the influenza vaccine market, as elderly individuals are at higher risk of developing severe complications from influenza.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of influenza vaccine. The growth and trends of influenza vaccine industry provide a holistic approach to this study.

Market Segmentation:

This section of the influenza vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

  • Inactivated
  • Live Attenuated

By Indication

  • Quadrivalent
  • Trivalent

By Age Group

  • Pediatric
  • Adult

By Route Of Administration

  • Injection
  • Nasal Spray

By Distribution Channel

  • Hospitals & Pharmacies
  • Government & Institutional Supply
  • Other

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Influenza Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the influenza vaccine market include GSK plc, AstraZeneca, SINOVAC, Pfizer Inc, Vaxess Technologies Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . INFLUENZA VACCINE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Vaccine Type
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By Route Of Administration
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY VACCINE TYPE

  • 6.1 Overview by Vaccine Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Vaccine Type
  • 6.4 Inactivated Historic and Forecast Sales by Regions
  • 6.5 Live Attenuated Historic and Forecast Sales by Regions

7 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Quadrivalent Historic and Forecast Sales by Regions
  • 7.5 Trivalent Historic and Forecast Sales by Regions

8 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY AGE GROUP

  • 8.1 Overview by Age Group
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Age Group
  • 8.4 Pediatric Historic and Forecast Sales by Regions
  • 8.5 Adult Historic and Forecast Sales by Regions

9 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 9.1 Overview by Route Of Administration
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Route Of Administration
  • 9.4 Injection Historic and Forecast Sales by Regions
  • 9.5 Nasal Spray Historic and Forecast Sales by Regions

10 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 10.1 Overview by Distribution Channel
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Distribution Channel
  • 10.4 Hospitals & Pharmacies Historic and Forecast Sales by Regions
  • 10.5 Government & Institutional Supply Historic and Forecast Sales by Regions
  • 10.6 Other Historic and Forecast Sales by Regions

11 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Top Company Share Analysis
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1. Overview, Historic and Forecast Sales Analysis
    • 11.3.2. North America By Segment Sales Analysis
    • 11.3.3. North America By Country Sales Analysis
    • 11.3.4. United State Sales Analysis
    • 11.3.5. Canada Sales Analysis
    • 11.3.6. Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1. Overview, Historic and Forecast Sales Analysis
    • 11.4.2. Europe by Segment Sales Analysis
    • 11.4.3. Europe by Country Sales Analysis
    • 11.4.4. United Kingdom Sales Analysis
    • 11.4.5. France Sales Analysis
    • 11.4.6. Germany Sales Analysis
    • 11.4.7. Italy Sales Analysis
    • 11.4.8. Russia Sales Analysis
    • 11.4.9. Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1. Overview, Historic and Forecast Sales Analysis
    • 11.5.2. Asia Pacific by Segment Sales Analysis
    • 11.5.3. Asia Pacific by Country Sales Analysis
    • 11.5.4. China Sales Analysis
    • 11.5.5. India Sales Analysis
    • 11.5.6. Japan Sales Analysis
    • 11.5.7. South Korea Sales Analysis
    • 11.5.8. Australia Sales Analysis
    • 11.5.9. Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1. Overview, Historic and Forecast Sales Analysis
    • 11.6.2. Latin America by Segment Sales Analysis
    • 11.6.3. Latin America by Country Sales Analysis
    • 11.6.4. Brazil Sales Analysis
    • 11.6.5. Argentina Sales Analysis
    • 11.6.6. Peru Sales Analysis
    • 11.6.7. Chile Sales Analysis
    • 11.6.8. Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1. Overview, Historic and Forecast Sales Analysis
    • 11.7.2. Middle East & Africa by Segment Sales Analysis
    • 11.7.3. Middle East & Africa by Country Sales Analysis
    • 11.7.4. Saudi Arabia Sales Analysis
    • 11.7.5. UAE Sales Analysis
    • 11.7.6. Israel Sales Analysis
    • 11.7.7. South Africa Sales Analysis
    • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE INFLUENZA VACCINE COMPANIES

  • 12.1. Influenza Vaccine Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13 . COMPANY PROFILES OF INFLUENZA VACCINE INDUSTRY

  • 13.1. Company Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. GSK plc
    • 13.3.1. Company Overview
    • 13.3.2. Company Revenue
    • 13.3.3. Products
    • 13.3.4. Recent Developments
  • 13.4. AstraZeneca
    • 13.4.1. Company Overview
    • 13.4.2. Company Revenue
    • 13.4.3. Products
    • 13.4.4. Recent Developments
  • 13.5. SINOVAC
    • 13.5.1. Company Overview
    • 13.5.2. Company Revenue
    • 13.5.3. Products
    • 13.5.4. Recent Developments
  • 13.6. Pfizer Inc
    • 13.6.1. Company Overview
    • 13.6.2. Company Revenue
    • 13.6.3. Products
    • 13.6.4. Recent Developments
  • 13.7. Vaxess Technologies Inc
    • 13.7.1. Company Overview
    • 13.7.2. Company Revenue
    • 13.7.3. Products
    • 13.7.4. Recent Developments
  • 13.8. CSL Limited
    • 13.8.1. Company Overview
    • 13.8.2. Company Revenue
    • 13.8.3. Products
    • 13.8.4. Recent Developments
  • 13.9. EMERGENT
    • 13.9.1. Company Overview
    • 13.9.2. Company Revenue
    • 13.9.3. Products
    • 13.9.4. Recent Developments
  • 13.10. Merck & Co. Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Company Revenue
    • 13.10.3. Products
    • 13.10.4. Recent Developments
  • 13.11. Viatris Inc.
    • 13.11.1. Company Overview
    • 13.11.2. Company Revenue
    • 13.11.3. Products
    • 13.11.4. Recent Developments
  • 13.12. OSIVAX
    • 13.12.1. Company Overview
    • 13.12.2. Company Revenue
    • 13.12.3. Products
    • 13.12.4. Recent Developments
  • 13.13. EMERGEX VACCINES
    • 13.13.1. Company Overview
    • 13.13.2. Company Revenue
    • 13.13.3. Products
    • 13.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Vaccine Type (USD MN)
  • Inactivated Market Sales by Geography (USD MN)
  • Live Attenuated Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • Quadrivalent Market Sales by Geography (USD MN)
  • Trivalent Market Sales by Geography (USD MN)
  • Analysis by Age Group (USD MN)
  • Pediatric Market Sales by Geography (USD MN)
  • Adult Market Sales by Geography (USD MN)
  • Analysis by Route Of Administration (USD MN)
  • Injection Market Sales by Geography (USD MN)
  • Nasal Spray Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospitals & Pharmacies Market Sales by Geography (USD MN)
  • Government & Institutional Supply Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Influenza Vaccine Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Influenza Vaccine Report
  • Market Research Process
  • Market Research Methodology
  • Global Influenza Vaccine Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Vaccine Type
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Age Group
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Vaccine Type (USD MN)
  • Inactivated Market Sales by Geography (USD MN)
  • Live Attenuated Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Quadrivalent Market Sales by Geography (USD MN)
  • Trivalent Market Sales by Geography (USD MN)
  • Global Market Analysis by Age Group (USD MN)
  • Pediatric Market Sales by Geography (USD MN)
  • Adult Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Injection Market Sales by Geography (USD MN)
  • Nasal Spray Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospitals & Pharmacies Market Sales by Geography (USD MN)
  • Government & Institutional Supply Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.